Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.52 |
| ▸ | LTK | P29376 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FER | P16591 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336371 | 0.81 | LRRK2 (0.55) | CA12CA9LRRK2DYRK1BLTK | |
| SCHEMBL2449133 | 0.81 | LRRK2 (0.55) | CA12CA9LRRK2DYRK1BLTK | |
| SCHEMBL4294892 | 0.76 | MEN1 (0.50) | LRRK2DYRK1BLTKPDGFRAFER | |
| SCHEMBL366728 | 0.73 | — | — | |
| SCHEMBL2420711 | 0.73 | LRRK2 (0.90) | LRRK2DYRK1BLTKPDGFRAFER | |
| SCHEMBL16962995 | 0.72 | LRRK2 (0.44) | LRRK2DYRK1BLTKPDGFRAFER | |
| SCHEMBL29355184 | 0.71 | CA12 (1.00) | CA12CA9LRRK2DYRK1BMAOA | |
| SCHEMBL4818277 | 0.71 | CA12 (1.00) | CA12CA9LRRK2DYRK1BMAOA | |
| SCHEMBL14896 | 0.71 | CA12 (1.00) | CA12CA9LRRK2DYRK1BMAOA | |
| SCHEMBL8213864 | 0.70 | CA12 (0.95) | CA12CA9LRRK2DYRK1BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2650274-B1 | A thionation process and a thionating agent | VIRONOVA THIONATION AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| US-9221855-B2 | Thionation process and a thionating agent | VIRONOVA THIONATION AB (SE) | 2015-12-29 | — | — | US | disclosed |
| US-9221855-B2 | Thionation process and a thionating agent | VIRONOVA THIONATION AB (SE) | 2015-12-29 | — | — | US | disclosed |
| US-9115158-B2 | Thionating agent | VIRONOVA THIONATION AB (SE) | 2015-08-25 | — | — | US | disclosed |
| US-9115158-B2 | Thionating agent | VIRONOVA THIONATION AB (SE) | 2015-08-25 | — | — | US | disclosed |
| US-20130303767-A1 | THIONATING AGENT | VIRONOVA THIONATION AB (SE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303767-A1 | THIONATING AGENT | VIRONOVA THIONATION AB (SE) | 2013-11-14 | — | — | US | disclosed |
| EP-2569263-B1 | A THIONATION PROCESS AND A THIONATING AGENT | VIRONOVA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| EP-2650274-A2 | A thionation process and a thionating agent | Vironova AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| US-20130102774-A1 | THIONATION PROCESS AND A THIONATING AGENT | VIRONOVA AB (SE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102774-A1 | THIONATION PROCESS AND A THIONATING AGENT | VIRONOVA AB (SE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012104415-A1 | A THIONATION PROCESS AND A THIONATING AGENT | VIRONOVA AB (SE) | 2012-08-09 | — | — | WO | disclosed |
| EP-2484655-A1 | A thionation process and a thionating agent | Vironova AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-5716951-A | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5705890-A | PLATELET AGGREGATION INHIBITOR, ANTITHROMBOTIC | GENENTECH, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0708775-B1 | TRICYCLIC INHIBITORS OF THE GPII b III a RECEPTOR | GENENTECH INC (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0708775-A1 | TRICYCLIC INHIBITORS OF THE GPII b III a RECEPTOR | GENENTECH INC (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5493020-A | ANTICOAGULANTS | GENENTECH, INC. (US) | 1996-02-20 | — | — | US | disclosed |
| WO-1995004057-A1 | TRICYCLIC INHIBITORS OF THE GPIIbIIIa RECEPTOR | GENENTECH, INC. (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102774-A1 | THIONATION PROCESS AND A THIONATING AGENT | NT5M, NT5E, NUDT5 | CA12 1993/4885CA9 1286/4885LRRK2 965/4885 |
| US-20130303767-A1 | THIONATING AGENT | NT5E, NT5C2, NUDT5 | CA12 2178/4885CA9 1341/4885LRRK2 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.